cGMP-dependent protein kinases (PKG) exhibit diverse physiological functions in the mammalian system e.g., in vascular and gastrointestinal smooth muscles, in platelets, in kidney, in bone growth, nociception and in the central nervous system. Furthermore, PKG were found in insects and in the malaria parasite Plasmodium falciparum. Two different genes of PKG exist: a) the PKG-I gene that is expressed as cytosolic PKG-Iα or PKG-Iβ isoform, and b) the PKG-II gene, which expresses the membrane associated PKG-II protein. The enzyme kinetics, the localization and the substrates of these PKG enzymes differ utilizing different physiological functions. Various inhibitors of PKG were developed directed against diverse functional regions of the kinase. These inhibitors of PKG have been used to analyse the specific functions of these enzymes. The review article will summarize these different inhibitors regarding their specificity and their present applications in vitro and in vivo. Furthermore, it will be discussed that the distinct inhibition of the PKG enzymes could be used as a valuable pharmacological target e.g., in the treatment of cardiovascular diseases, diarrhea, cancer or malaria.
References
[1]
Ono-Saito, N.; Niki, I.; Hidaka, H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol. Ther. 1999, 82, 123–131, doi:10.1016/S0163-7258(98)00070-9.
[2]
Pinkse, M.W.; Rijkers, D.T.; Dostmann, W.R.; Heck, A.J. Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry. The J. Biol. Chem. 2009, 284, 16354–16368, doi:10.1074/jbc.M808521200.
[3]
Smolenski, A.; Burkhardt, A.M.; Eigenthaler, M.; Butt, E.; Gambaryan, S.; Lohmann, S.M.; Walter, U. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn-Schmied. Arch. Pharmacol. 1998, 358, 134–139, doi:10.1007/PL00005234.
[4]
Hofmann, F. The biology of cyclic GMP-dependent protein kinases. J. Biol. Chem. 2005, 280, 1–4.
[5]
Hofmann, F.; Ammendola, A.; Schlossmann, J. Rising behind NO: cGMP-dependent protein kinases. J. Cell Sci. 2000, 113, 1671–1676.
[6]
Hofmann, F.; Bernhard, D.; Lukowski, R.; Weinmeister, P. cGMP regulated protein kinases (cGK). Handb. Exp. Pharm. 2009, 137–162.
[7]
Lee, J.H.; Li, S.; Liu, T.; Hsu, S.; Kim, C.; Woods, V.L., Jr.; Casteel, D.E. The amino terminus of cGMP-dependent protein kinase Ibeta increases the dynamics of the protein's cGMP-binding pockets. Int. J. Mass. Spectrom. 2011, 302, 44–52.
[8]
Busch, J.L.; Bessay, E.P.; Francis, S.H.; Corbin, J.D. A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity. J. Biol. Chem. 2002, 277, 34048–34054.
[9]
Pohler, D.; Butt, E.; Meissner, J.; Muller, S.; Lohse, M.; Walter, U.; Lohmann, S.M.; Jarchau, T. Expression, purification, and characterization of the cGMP-dependent protein kinases I beta and II using the baculovirus system. FEBS Lett. 1995, 374, 419–425, doi:10.1016/0014-5793(95)01168-E.
Richie-Jannetta, R.; Busch, J. L.; Higgins, K.A.; Corbin, J. D.; Francis, S.H. Isolated regulatory domains of cGMP-dependent protein kinase Ialpha and Ibeta retain dimerization and native cGMP-binding properties and undergo isoform-specific conformational changes. J. Biol. Chem. 2006, 281, 6977–6984, doi:10.1074/jbc.M510886200.
[12]
Wooldridge, A.A.; MacDonald, J.A.; Erdodi, F.; Ma, C.; Borman, M.A.; Hartshorne, D.J.; Haystead, T.A. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J. Biol. Chem. 2004, 279, 34496–34504.
[13]
Ellerbroek, S.M.; Wennerberg, K.; Burridge, K. Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 2003, 278, 19023–19031, doi:10.1074/jbc.M213066200.
[14]
Schlossmann, J.; Ammendola, A.; Ashman, K.; Zong, X.; Huber, A.; Neubauer, G.; Wang, G.X.; Allescher, H. D.; Korth, M.; Wilm, M.; Hofmann, F.; Ruth, P. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature 2000, 404, 197–201.
[15]
Golin-Bisello, F.; Bradbury, N.; Ameen, N. STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G. Amer. J. Physiol-Cell Physiol. 2005, 289, C708–C716, doi:10.1152/ajpcell.00544.2004.
[16]
Chikuda, H.; Kugimiya, F.; Hoshi, K.; Ikeda, T.; Ogasawara, T.; Kamekura, S.; Ogata, N.; Nakamura, K.; Chung, U.I.; Kawaguchi, H. Mutation in cGMP-dependent protein kinase II causes dwarfism in a rat mutant KMI through uncoupling of proliferation and differentiation of chondrocytes. J. Bone Miner. Metab. 2005, 23, 200–204, doi:10.1007/s00774-004-0598-8.
[17]
Forte, L.R.; London, R.M.; Krause, W.J.; Freeman, R.H. Mechanisms of guanylin action via cyclic GMP in the kidney. Annu. Rev. Physiol. 2000, 62, 673–695, doi:10.1146/annurev.physiol.62.1.673.
[18]
Rangaswami, H.; Marathe, N.; Zhuang, S.; Chen, Y.; Yeh, J.C.; Frangos, J.A.; Boss, G.R.; Pilz, R.B. Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J. Biol. Chem. 2009, 284, 14796–14808.
[19]
Gambaryan, S.; Wagner, C.; Smolenski, A.; Walter, U.; Poller, W.; Haase, W.; Kurtz, A.; Lohmann, S.M. Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells. Proc. Natl. Acad. Sci. USA 1998, 95, 9003–9008.
[20]
Schlossmann, J.; Feil, R.; Hofmann, F. Signaling through NO and cGMP-dependent protein kinases. Ann. Med. 2003, 35, 21–27.
[21]
Butt, E. cGMP-dependent protein kinase modulators. Handb. Exp. Pharm. 2009, 409–421, doi:10.1007/978-3-540-68964-5_17.
[22]
Schwede, F.; Maronde, E.; Genieser, H.; Jastorff, B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 2000, 87, 199–226, doi:10.1016/S0163-7258(00)00051-6.
[23]
Burkhardt, M.; Glazova, M.; Gambaryan, S.; Vollkommer, T.; Butt, E.; Bader, B.; Heermeier, K.; Lincoln, T.M.; Walter, U.; Palmetshofer, A. KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J. Biol. Chem. 2000, 275, 33536–33541.
[24]
Butt, E.; Pohler, D.; Genieser, H.G.; Huggins, J.P.; Bucher, B. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. Brit. J. Pharmacol. 1995, 116, 3110–3116, doi:10.1111/j.1476-5381.1995.tb15112.x.
[25]
Butt, E.; van Bemmelen, M.; Fischer, L.; Walter, U.; Jastorff, B. Inhibition of cGMP-dependent protein kinase by (Rp)-guanosine 3',5'-monophosphorothioates. FEBS Lett. 1990, 263, 47–50, doi:10.1016/0014-5793(90)80702-K.
[26]
Butt, E.; Abel, K.; Krieger, M.; Palm, D.; Hoppe, V.; Hoppe, J.; Walter, U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 1994, 269, 14509–14517.
[27]
Vaandrager, A.B.; Bot, A.G.; De Jonge, H.R. Guanosine 3',5'-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine. Gastroenterology 1997, 112, 437–443, doi:10.1053/gast.1997.v112.pm9024297.
[28]
Hidaka, H.; Kobayashi, R. Pharmacology of protein kinase inhibitors. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 377–397, doi:10.1146/annurev.pa.32.040192.002113.
[29]
Engh, R.A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J. Biol. Chem. 1996, 271, 26157–26164.
[30]
Dostmann, W.R.; Taylor, M.S.; Nickl, C.K.; Brayden, J.E.; Frank, R.; Tegge, W.J. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc. Nat. Acad. Sci. USA 2000, 97, 14772–14777, doi:10.1073/pnas.97.26.14772.
[31]
Dostmann, W.R.; Tegge, W.; Frank, R.; Nickl, C.K.; Taylor, M.S.; Brayden, J.E. Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Ialpha. Pharmacol. Ther. 2002, 93, 203–215, doi:10.1016/S0163-7258(02)00189-4.
[32]
Gambaryan, S.; Butt, E.; Kobsar, A.; Geiger, J.; Rukoyatkina, N.; Parnova, R.; Nikolaev, V.O.; Walter, U. The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells. Brit. J. Pharmacol. 2012, 167, 826–838, doi:10.1111/j.1476-5381.2012.02044.x.
[33]
Foley, K.F.; De Frutos, S.; Laskovski, K.E.; Tegge, W.; Dostmann, W. R. Culture conditions influence uptake and intracellular localization of the membrane permeable cGMP-dependent protein kinase inhibitor DT-2. Front Biosci. 2005, 10, 1302–1312, doi:10.2741/1620.
[34]
Nickl, C.K.; Raidas, S.K.; Zhao, H.; Sausbier, M.; Ruth, P.; Tegge, W.; Brayden, J.E.; Dostmann, W.R. (D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha. Biochim. Biophys. Acta 2010, 1804, 524–532, doi:10.1016/j.bbapap.2009.12.004.
[35]
Vaandrager, A.B.; Edixhoven, M.; Bot, A.G.; Kroos, M.A.; Jarchau, T.; Lohmann, S.; Genieser, H.G.; de Jonge, H.R. Endogenous type II cGMP-dependent protein kinase exists as a dimer in membranes and can Be functionally distinguished from the type I isoforms. J. Biol. Chem. 1997, 272, 11816–11823.
[36]
Gurnett, A.M.; Liberator, P.A.; et al. Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target. J. Biol. Chem. 2002, 277, 15913–15922, doi:10.1074/jbc.M108393200.
[37]
Koeppen, M.; Feil, R.; Siegl, D.; Feil, S.; Hofmann, F.; Pohl, U.; de Wit, C. cGMP-dependent protein kinase mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Hypertension 2004, 44, 952–955, doi:10.1161/01.HYP.0000147661.80059.ca.
[38]
Pfeifer, A.; Klatt, P.; Massberg, S.; Ny, L.; Sausbier, M.; Hirneiss, C.; Wang, G. X.; Korth, M.; Aszodi, A.; Andersson, K.E.; Krombach, F.; Mayerhofer, A.; Ruth, P.; Fassler, R.; Hofmann, F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998, 17, 3045–3051.
[39]
Sausbier, M.; Schubert, R.; Voigt, V.; Hirneiss, C.; Pfeifer, A.; Korth, M.; Kleppisch, T.; Ruth, P.; Hofmann, F. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ. Res. 2000, 87, 825–830, doi:10.1161/01.RES.87.9.825.
[40]
Weber, S.; Bernhard, D.; Lukowski, R.; Weinmeister, P.; Worner, R.; Wegener, J. W.; Valtcheva, N.; Feil, S.; Schlossmann, J.; Hofmann, F.; Feil, R. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ. Res. 2007, 101, 1096–1103, doi:10.1161/CIRCRESAHA.107.154351.
[41]
Surks, H.K.; Mochizuki, N.; Kasai, Y.; Georgescu, S.P.; Tang, K.M.; Ito, M.; Lincoln, T.M.; Mendelsohn, M.E. Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. Science 1999, 286, 1583–1587, doi:10.1126/science.286.5444.1583.
[42]
Robertson, B.E.; Schubert, R.; Hescheler, J.; Nelson, M.T. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Amer. J. Physiol. 1993, 265, C299–C303.
Ozaki, M.; Kawashima, S.; Yamashita, T.; Hirase, T.; Namiki, M.; Inoue, N.; Hirata, K.; Yasui, H.; Sakurai, H.; Yoshida, Y.; Masada, M.; Yokoyama, M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J. Clin. Invest. 2002, 110, 331–340.
[47]
Shi, W.; Wang, X.; Shih, D.M.; Laubach, V.E.; Navab, M.; Lusis, A.J. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 2002, 105, 2078–2082, doi:10.1161/01.CIR.0000015853.59427.32.
[48]
Chen, J.; Kuhlencordt, P.J.; Astern, J.; Gyurko, R.; Huang, P.L. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001, 104, 2391–2394, doi:10.1161/hc4501.099729.
[49]
Knowles, J.W.; Reddick, R.L.; Jennette, J.C.; Shesely, E.G.; Smithies, O.; Maeda, N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J. Clin. Invest. 2000, 105, 451–458, doi:10.1172/JCI8376.
[50]
Wong, J.C.; Fiscus, R.R. Protein kinase G activity prevents pathological-level nitric oxide-induced apoptosis and promotes DNA synthesis/cell proliferation in vascular smooth muscle cells. Cardiovasc. Pathol. 2010, 19, e221–e231, doi:10.1016/j.carpath.2009.11.001.
[51]
Wolfsgruber, W.; Feil, S.; Brummer, S.; Kuppinger, O.; Hofmann, F.; Feil, R. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells. Proc. Natl. Acad. Sci. US A 2003, 100, 13519–13524, doi:10.1073/pnas.1936024100.
[52]
Weinmeister, P.; Lukowski, R.; Linder, S.; Traidl-Hoffmann, C.; Hengst, L.; Hofmann, F.; Feil, R. Cyclic guanosine monophosphate-dependent protein kinase I promotes adhesion of primary vascular smooth muscle cells. Mol. Biol. Cell. 2008, 19, 4434–4441, doi:10.1091/mbc.E08-04-0370.
[53]
Lincoln, T.M.; Wu, X.; Sellak, H.; Dey, N.; Choi, C.S. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front. Biosci. 2006, 11, 356–367, doi:10.2741/1803.
[54]
Owens, G.K.; Kumar, M.S.; Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004, 84, 767–801.
[55]
Lukowski, R.; Weinmeister, P.; Bernhard, D.; Feil, S.; Gotthardt, M.; Herz, J.; Massberg, S.; Zernecke, A.; Weber, C.; Hofmann, F.; Feil, R. Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1244–1250, doi:10.1161/ATVBAHA.108.166405.
[56]
Joshi, C.N.; Martin, D.N.; Fox, J.C.; Mendelev, N.N.; Brown, T.A.; Tulis, D.A. The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J. Pharmacol. Exp. Ther. 2011, 339, 394–402, doi:10.1124/jpet.111.183400.
Kim, B.J.; Lee, J.H.; Jun, J.Y.; Chang, I.Y.; So, I.; Kim, K.W. Vasoactive intestinal polypeptide inhibits pacemaker activity via the nitric oxide-cGMP-protein kinase G pathway in the interstitial cells of Cajal of the murine small intestine. Mol. Cells 2006, 21, 337–342, doi:10.1016/j.molcel.2006.01.011.
[59]
Vaandrager, A.B.; Bot, A.G.; Ruth, P.; Pfeifer, A.; Hofmann, F.; De Jonge, H.R. Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon. Gastroenterology 2000, 118, 108–114.
[60]
Vaandrager, A.B.; Smolenski, A.; Tilly, B.C.; Houtsmuller, A.B.; Ehlert, E.M.; Bot, A.G.; Edixhoven, M.; Boomaars, W.E.; Lohmann, S.M.; de Jonge, H.R. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation. Proc. Nat. Acad. Sci. USA 1998, 95, 1466–1471.
[61]
Pfeifer, A.; Aszodi, A.; Seidler, U.; Ruth, P.; Hofmann, F.; Fassler, R. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 1996, 274, 2082–2086.
[62]
Chikuda, H.; Kugimiya, F.; Hoshi, K.; Ikeda, T.; Ogasawara, T.; Shimoaka, T.; Kawano, H.; Kamekura, S.; Tsuchida, A.; Yokoi, N.; Nakamura, K.; Komeda, K.; Chung, U. I.; Kawaguchi, H. Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. Gene Dev. 2004, 18, 2418–2429, doi:10.1101/gad.1224204.
[63]
Kawasaki, Y.; Kugimiya, F.; Chikuda, H.; Kamekura, S.; Ikeda, T.; Kawamura, N.; Saito, T.; Shinoda, Y.; Higashikawa, A.; Yano, F.; Ogasawara, T.; Ogata, N.; Hoshi, K.; Hofmann, F.; Woodgett, J.R.; Nakamura, K.; Chung, U.I.; Kawaguchi, H. Phosphorylation of GSK-3beta by cGMP-dependent protein kinase II promotes hypertrophic differentiation of murine chondrocytes. J. Clin. Invest. 2008, 118, 2506–2515.
[64]
Rangaswami, H.; Marathe, N.; Zhuang, S.; Chen, Y.; Yeh, J. C.; Frangos, J.A.; Boss, G.R.; Pilz, R.B. Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J. Biol. Chem. 2009, 284, 14796–14808.
[65]
Rangaswami, H.; Schwappacher, R.; Tran, T.; Chan, G.C.; Zhuang, S.; Boss, G.R.; Pilz, R.B. Protein kinase G and focal adhesion kinase converge on Src/Akt/beta-catenin signaling module in osteoblast mechanotransduction. J. Biol. Chem. 2012, 287, 21509–21519.
[66]
Wong, J.C.; Fiscus, R.R. Essential roles of the nitric oxide (no)/cGMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway and the atrial natriuretic peptide (ANP)/cGMP/PKG-Ialpha autocrine loop in promoting proliferation and cell survival of OP9 bone marrow stromal cells. J. Cell. Biochem. 2011, 112, 829–839, doi:10.1002/jcb.22981.
[67]
Johlfs, M.G.; Fiscus, R.R. Protein kinase G type-Ialpha phosphorylates the apoptosis-regulating protein Bad at serine 155 and protects against apoptosis in N1E-115 cells. Neurochem. Int. 2010, 56, 546–553, doi:10.1016/j.neuint.2009.12.017.
[68]
Leung, E.L.; Wong, J.C.; Johlfs, M.G.; Tsang, B.K.; Fiscus, R.R. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol. Cancer Res. 2010, 8, 578–591, doi:10.1158/1541-7786.MCR-09-0178.
[69]
Wong, J.C.; Bathina, M.; Fiscus, R.R. Cyclic GMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Ialpha kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J. Cell. Biochem. 2012, 113, 3587–3598, doi:10.1002/jcb.24237.
[70]
Babykutty, S.; Suboj, P.; Srinivas, P.; Nair, A.S.; Chandramohan, K.; Gopala, S. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin. Exp. Metastas. 2012, 29, 471–492, doi:10.1007/s10585-012-9464-6.
[71]
Hou, Y.; Wong, E.; Martin, J.; Schoenlein, P.V.; Dostmann, W.R.; Browning, D.D. A role for cyclic-GMP dependent protein kinase in anoikis. Cell. signal. 2006, 18, 882–888.
[72]
Fallahian, F.; Karami-Tehrani, F.; Salami, S.; Aghaei, M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS. J. 2011, 278, 3360–3369, doi:10.1111/j.1742-4658.2011.08260.x.
[73]
Taylor, H.M.; McRobert, L.; Grainger, M.; Sicard, A.; Dluzewski, A.R.; Hopp, C.S.; Holder, A.A.; Baker, D.A. The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony. Eukaryot. Cell 2010, 9, 37–45, doi:10.1128/EC.00186-09.
[74]
Hopp, C.S.; Flueck, C.; Solyakov, L.; Tobin, A.; Baker, D.A. Spatiotemporal and Functional Characterisation of the Plasmodium falciparum cGMP-Dependent Protein Kinase. PloS One 2012, 7, e48206.
[75]
Wiersma, H.I.; Galuska, S.E.; Tomley, F.M.; Sibley, L.D.; Liberator, P.A.; Donald, R.G. A role for coccidian cGMP-dependent protein kinase in motility and invasion. Int. J. Parasitol. 2004, 34, 369–380, doi:10.1016/j.ijpara.2003.11.019.
